Robert Li, PhD

Co-founder & Chief Executive Officer

Robert Li is a seasoned drug developer with 15+ years of industry experience in translational research and development, within therapeutic areas of immunology, oncology, and cancer immunology. He held multiple leadership roles such as biotech executive, cross functional team lead and immunology therapeutic area lead-safety assessment in global pharmaceutical companies (Bristol-Myers Squibb, Genentech, and Vir Biotechnology etc.). He leads/supports the achievement of developmental milestones (e.g., IND, Pivotal trial, NDA/BLA, and global regulatory interactions) for more than 10 small and large molecules. He is frequently invited as speaker, chair, and/or panelist for global conferences such as AACR-FDA workshop, CDE workshop, SOT annual meeting, BioSafe annual meeting, Bispecific summit, JP Morgan regional expert meeting, BiG meeting etc.

Dr. Li received a Ph.D. in immunotoxicology from the University of Toronto, followed by a postdoctoral training at Hoffmann-La Roche. He is the President for the SOT Biotechnology Specialty Section from 2021-2022. Dr. Li is also the SOT award recipient of the Outstanding Young Immunotoxicologist in 2017 and the Outstanding Young Investigator in Biotechnology in 2018.